Page 84 - Read Online

Moia et al. J Cancer Metastasis Treat 2019;5:67 I http://dx.doi.org/10.20517/2394-4722.2019.020 Page 7 of 8

REFERENCES

1. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American
Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018;36:1631-41.
2. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol
2017;14:531-48.
3. Arzuaga-Mendez J, Prieto-Fernández E, Lopez-Lopez E, Martin-Guerrero I, García-Ruiz JC, et al. Cell-free DNA as a biomarker in
diffuse large B-cell lymphoma: a systematic review. Crit Rev Oncol Hematol 2019;139:7-15.
4. Melani C, Wilson WH, Roschewski M. Liquid biopsy in non-Hodgkin’s lymphoma. Hematol Oncol 2019;37 Suppl 1:70-4.
5. Crombie J, Armand P. The emerging role of liquid biopsies in lymphoproliferative disorders. Curr Hematol Malig Rep 2019;14:11-21.
6. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, et al. Liquid biopsies come of age: towards implementation of
circulating tumour DNA. Nat Rev Cancer 2017;17:223-38.
7. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an in vivo nucleosome footprint that informs its
tissues-of-origin. Cell 2016;164:57-68.
8. Rossi D, Condoluci A, Spina V, Gaidano G. Methods for measuring ctDNA in lymphomas. Methods Mol Biol 2019;1881:253-65.
9. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta
2013;424:222-30.
10. Streck (2014) Cell-free DNA BCT: instructions for use. Omaha, NE. Available from: https://www.streck.com/news/2016-09-19-Streck-
announces-blood-collection-tube-forcell-free- plasma-RNA.aspx. [Last accessed on 2 Sep 2019]
11. Qiagen (2013) QIAamp® circulating nucleic acid handbook. 3rd ed. Available from: https://www.qiagen.com/us/resources/download.
aspx? id1⁄40c4b31ab-f4fb-425f-99bf- 10ab9538c061&lang1⁄4en. [Last accessed on 2 Sep 2019]
12. Pérez-Barrios C, Nieto-Alcolado I, Torrente M, Jiménez-Sánchez C, Calvo V, et al. Comparison of methods for circulating cell-free
DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res 2016;5:665-72.
13. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by
immunoglobulin high-throughput sequencing. Blood 2015;125:3679-87.
14. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, et al. Circulating tumour DNA and CT monitoring in patients with
untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015;16:541-9.
15. Rossi D, Spina V, Bruscaggin A, Gaidano G. Liquid biopsy in lymphoma. Haematologica 2019;104:648-52.
16. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, et al. An ultrasensitive method for quantitating circulating tumor DNA with
broad patient coverage. Nat Med 2014;20:548-54.
17. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, et al. Diffuse large B-cell lymphoma: ESMO Clinical Practice Guidelines.
Ann Oncol 2015;26:v116-25.
18. Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv19-29.
19. Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, et al. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular
lymphoma. Leukemia 2018;32:1261-5.
20. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood
2017;129:1947-57.
21. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse
large B-cell lymphoma. J Clin Oncol 2018;36:2845-53.
22. Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 2015;52:67-76.
23. Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, et al. Circulating tumor DNA reveals genetics, clonal evolution, and
residual disease in classical Hodgkin lymphoma. Blood 2018;131:2413-25.
24. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, et al. The predictive value of positron emission tomography scanning performed
after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 2006;91:475-81.
25. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission
tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint
Italian-Danish study. J Clin Oncol 2007;25:3746-52.
26. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-
analysis. Br J Haematol 2015;170:356-66.
27. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, et al. Dynamic risk profiling using serial tumor biomarkers for personalized
outcome prediction. Cell 2019;178:699-713.e19.
28. ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy in Mature B-cell Tumors. Identifier NCT03280394. Available
from: https://clinicaltrials.gov/ct2/show/NCT03280394. [Last accessed on 2 Sep 2019]
29. ClinicalTrials.gov. National Library of Medicine (U.S.). Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA).
Identifier NCT02883517. Available from: https://clinicaltrials.gov/ct2/show/NCT02883517. [Last accessed on 2 Sep 2019]
30. ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy Evaluation and Repository Development at Princess Margaret
(LIBERATE). Identifier NCT03702309. Available from: https://clinicaltrials.gov/ct2/show/NCT03702309. [Last accessed on 2 Sep 2019]
31. Wedge E, Hansen JW, Garde C, Asmar F, Tholstrup D, et al. Global hypomethylation is an independent prognostic factor in diffuse